Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Product Highlight - Spiolto Respimat

01 May 2018
SPIOLTO RESPIMAT - Tiotropium 2.5 mcg, Olodaterol 2.5 mcg inhalation soln - Boehringer Ingelheim

The Only LAMA/LABA with the active ingredient of SPIRIVA inside (Tiotropium)
Start SPIOLTO RESPIMAT early for your patients
• Starts working within 5 minutes after the first dose1
• Improves lung function, lasts for 24 hours1,2
• Consistently reduces the need for rescue medication beyond SPIRIVA7
• Contains SPIRIVA which has unsurpassed long-term data in EXACERBATION3
• Respimat is designed for deep lung deposition4-6 and all your patients need to do
  is breathe in naturally7

References:
1. SPIOLTO RESPIMAT Summary of Product Characteristics, March 2016
2. Beeh KM. Pulm Pharmacol Ther 2015;32:53-59.
3. Tashkin DP, et al. N Engl J Med 2008;21:159-168.
4. Newman SP, et al. Chest 1998;113:957-963
5. Pitcairn G, et al. J Aerosol Med 2005;18:264-272.
6. Peterson JB, et al. J Aerosol Med Pulm Drug Del 2008;21:159-168.
7. SPIRIVA RESPIMAT Summary of Product Characteristics, Nov 2017

Further information is available in section 3b and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.